Robert Sidbury, MD, MPH
Professor, Dermatology
Department of Pediatrics
University of Washington

PRESENTATION OBJECTIVES:
1. Highlight newly described co-morbidities
2. Discuss new topical therapies
3. Review newly FDA approved systemic agents and promising pipeline drugs

DISCLOSURES:
Robert Sidbury, MD, MPH, has the following financial relationships:
• Investigator: Sanofi-Regeneron (Dupilumab)
• Consultant: Lilly (Lebrikizumab); Leo (Tralokinumab)
• Co-chair: American Academy of Dermatology AD Guidelines of Care Committee

свернуть